Additional Therapies For R/R Cll

Additional Therapies for R/R CLL

Sequencing of therapies in patients with R/R CLL

VJHemOnc – Video Journal of Hematology & HemOnc

R/R CLL: combination therapy and tailored treatment

VJHemOnc – Video Journal of Hematology & HemOnc

How to approach R/R CLL

VJHemOnc – Video Journal of Hematology & HemOnc

There Are Multiple Ways to Treat R/R CLL or R/R MCL: What Would the Experts Do?

Therapeutic Approaches for R/R CLL

Novel Treatment Options in CLL

Are combination therapies more effective for the treatment of relapsed refractory CLL?

VJHemOnc – Video Journal of Hematology & HemOnc

What novel targeted therapies are currently under investigation for R/R CLL?

Insights into the role of novel BTKis in the treatment landscape of R/R CLL

VJHemOnc – Video Journal of Hematology & HemOnc

VENICE I: venetoclax in R/R CLL patients

VJHemOnc – Video Journal of Hematology & HemOnc

Updates in CLL - 2023 Best of Hematology Conference

Total Health | Oncology

The latest CLL treatments and therapies with Dr Jan Burger

Leukaemia Foundation - Blood Cancer Information

Latest updates on liso-cel for R/R CLL/SLL

VJHemOnc – Video Journal of Hematology & HemOnc

Is acalabrutinib superior to ibrutinib for the treatment of R/R CLL?

What’s New In Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

EHA2024 Chronic Lymphocytic Leukemia Preview: The Road Ahead With Targeted Therapies

Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of R/R CLL and SLL

42-Month Follow-Up Data of Acalabrutinib Monotherapy in R/R CLL

Targeted Oncology

Venetoclax in RR CLL